Why the study?
Patients with septic shock and refractory hypotension despite fluid resuscitation and high-dose noradrenaline have high mortality, and questions remain regarding how angiotensin II impacts outcomes and which patients benefit most.
Does angiotensin II therapy improve clinical outcomes in patients with refractory septic shock?
Does angiotensin II therapy improve clinical outcomes in patients with refractory septic shock?
This narrative review summarizes the pathophysiology and potential clinical benefits of angiotensin II therapy in patients with refractory septic shock.
Answers are grounded in this paper and cite their sources.
Angiotensin II shows promise in refractory septic shock; leaves open confirmation versus vasopressin in RCTs.
Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 µg/kg/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes. This narrative review aims to provide an overview of the pathophysiology of the renin-angiotensin system and the role of endogenous angiotensin II in vasodilatory shock with a focus on how angiotensin II treatment impacts clinical outcomes and on identifying the population that may benefit most from its use.
No takes yet. Share an insight, caveat, or question.
Coloretti et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: